BioCentury
ARTICLE | Financial News

argenx raises EUR 30 million

June 4, 2016 12:18 AM UTC

argenx N.V. (Euronext:ARGX) raised EUR 30 million ($33.4 million) through the sale of 2.7 million shares at EUR 11.10 in a private placement, mainly with U.S. investors. The price was a 3% discount to argenx's close of EUR 11.40 on May 31, the day before it announced the deal. Investors included Aquilo Capital, Burrage Capital, Dafna Capital, MPM Oncology Impact Fund and Perceptive Advisors, along with other existing and new institutional investors.

argenx has four molecules in Phase I testing derived from its SIMPLE antibody platform. It expects data next quarter from a Phase I study of ARGX-110, a human mAb against CD70 (CD27L), to treat T cell lymphoma. ...